Dr. Jacques Brown graduated from medical school and completed his residency in Internal Medicine at Laval University. He finished his residency in rheumatology at Université de Sherbrooke before undertaking post-doctoral training in metabolic bone diseases at the INSERM unit in Lyon, France.
He is a clinical researcher at the Centre de recherche du CHU de Québec-Laval University and a clinical professor at the Department of Medicine at Laval University. His major research interest is metabolic bone disorders such as Paget’s disease of bone, and osteoporosis.
Through the characterization of three French-Canadian families with Paget’s disease of bone, he first contributed to the discovery (2001) of the SQSTM1 gene mutations linked to this disease. In collaboration with Dr. Laëtitia Michou, this cohort now contains 43 families, 263 unrelated individuals with Paget’s disease and 298 controls, totalling 1,426 DNA samples with detailed phenotypes. The recruitment of new families and unrelated patients continues to help better identify new genetic factors of Paget’s disease of bone.
Since 1994, he has been a co-principal investigator and Quebec Centre Director on the Canadian Multicentre Osteoporosis Study (CaMOS), an epidemiologic study looking at the prevalence of osteoporosis, as well as the incidence of osteoporotic fractures in a large cohort (9,400 subjects) of the Canadian population. He is the principal investigator of the Recognizing Osteoporosis and its Consequences Programme, a patient health-management programme aimed at evaluating the diagnostic and treatment care gaps for osteoporosis following a fragility fracture in women 50 years of age and over.
He has published over 240 scientific articles in several high-impact journals. He has received several distinctions, including two John G. Haddad Jr. Research Awards from the Paget’s Foundation (2003 and 2005) and the Lindy-Fraser Memorial Award from Osteoporosis Canada (2004) for his work on the clinical practice guidelines of osteoporosis. In 2009, he was knighted to the Ordre National du Québec. More recently, Dr. Brown received the 2017 Distinguished Investigator Award from the Canadian Rheumatology Association for his exceptional contribution to rheumatology in Canada, and the Council of Physicians, Pharmacists, and Dentists of the CHU de Québec has awarded him the Diamant Hommage Héritage for the development and accomplishment of his career which will leave a solid legacy for the future of the institution.
2705, boulevard Laurier
Canada G1V 4G2
Data not available
Current use of bone turnover markers in the management of osteoporosisJournal Article
Clin Biochem, 2022.
Romosozumab Enhances Vertebral Bone Structure in Women With Low Bone DensityJournal Article
J Bone Miner Res, 37 (2), 2022.
The diagnosis of osteoporotic vertebral fractures reduxJournal Article
Clin Radiol, 77 (1), 2022.
Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in CanadaJournal Article
Arch Osteoporos, 17 (1), 2022.
Bone Mineral and Organic Properties in Postmenopausal Women Treated With Denosumab for Up to 10 yearsJournal Article
J Bone Miner Res, 37 (5), 2022.
Attenuated clinical and osteoclastic phenotypes of Paget's disease of bone linked to the p.Pro392Leu/SQSTM1 mutation by a rare variant in the DOCK6 geneJournal Article
BMC Med Genomics, 15 (1), 2022.
Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results From the FRAME Clinical TrialJournal Article
J Bone Miner Res, 37 (1), 2022.
Hip fracture predicts subsequent hip fracture: a retrospective observational study to support a call to early hip fracture prevention efforts in post-fracture patientsJournal Article
Osteoporos Int, 33 (1), 2022.
Where's the break? Critique of radiographic vertebral fracture diagnostic methodsJournal Article
Osteoporos Int, 32 (12), 2021.
Prediction of Osteoporotic Fractures in Elderly Individuals: A Derivation and Internal Validation Study Using Healthcare Administrative DataJournal Article
J Bone Miner Res, 36 (12), 2021.
- Clinical validity and clinical utility of a screening test for Paget's disease of bone, from 2019-03-01 to 2023-03-31